{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T10:13:44Z","timestamp":1769854424993,"version":"3.49.0"},"reference-count":23,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"49","license":[{"start":{"date-parts":[[2022,12,9]],"date-time":"2022-12-09T00:00:00Z","timestamp":1670544000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,12,9]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Coronary heart disease (CHD) is the leading cause of human death in the world and a public health problem of global concern. As a common arrhythmia in CHD, premature ventricular contractions are very likely to progress to fatal arrhythmias, resulting in serious adverse consequences. At present, the treatment of premature ventricular contractions due to CHD mainly focuses on catheter ablation, beta-blockers and antiarrhythmics. Both require ongoing monitoring because relapses may lead to redevelopment of cardiomyopathy, and there are varying degrees of indications and side effects. Several clinical studies have shown that Xinmai\u2019an can effectively control the occurrence of premature ventricular contractions and reduce the risk of recurrence. However, there is currently no systematic review evaluating its effectiveness. Therefore, the purpose of this study is to provide strong evidence-based medical evidence for Xinmai\u2019an tablet in the treatment of premature ventricular contractions due to CHD.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>We will search the main Chinese and English databases from inception to June 5, 2022. And identified as the randomized controlled trials. In addition, a reference list of studies meeting the inclusion criteria will be retrieved. Two researchers will conduct literature screening and quality evaluation. And we will conduct bias risk assessment and sensitivity analysis. The analysis software uses RevMan 5.3.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Mainly by observing the number of ventricular premature beat attacks (24-hour holter monitoring electrocardiogram), electrocardiogram efficacy (ST segment and T wave changes) and echocardiogram assesses the structure and function of the left and right ventricular, left ventricular ejection fraction, etc. To evaluate the clinical effect of Xinmai\u2019an on premature ventricular contractions due to CHD.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>The results of this study will provide a basis for the selection of treatment options for premature ventricular contractions due to CHD.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000032253","type":"journal-article","created":{"date-parts":[[2023,1,12]],"date-time":"2023-01-12T21:33:35Z","timestamp":1673559215000},"page":"e32253","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Efficacy and safety of Xinmai\u2019an tablet in treatment of premature ventricular contractions due to coronary heart disease: A protocol for systematic review and meta-analysis"],"prefix":"10.1097","volume":"101","author":[{"given":"Meiling","family":"Wang","sequence":"first","affiliation":[{"name":"School of Traditional Chinese Medicine, Changchun University of Traditional Chinese Medicine, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sihua","family":"Che","sequence":"additional","affiliation":[{"name":"School of Traditional Chinese Medicine, Changchun University of Traditional Chinese Medicine, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weiwei","family":"Pan","sequence":"additional","affiliation":[{"name":"Changchun Medical College, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shumao","family":"Zhang","sequence":"additional","affiliation":[{"name":"Rehabilitation Hospital of Jilin Province Disabled People\u2019s Federation, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2224-4175","authenticated-orcid":false,"given":"Guijun","family":"Shi","sequence":"additional","affiliation":[{"name":"Changchun Chinese Medicine Hospital, China."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/S0002-9149(77)80121-5","article-title":"Ventricular premature beats and anatomically defined coronary heart disease.","volume":"39","author":"Calvert","year":"1977","journal-title":"Am J Cardiol"},{"key":"R2-20250504","first-page":"5086","article-title":"The therapeutical effect of Chinese medicine for the treatment of atherosclerotic coronary heart disease.","volume":"23","author":"Zhang","year":"2017","journal-title":"Curr Pharm Des"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1136\/heartjnl-2020-318628","article-title":"Management of premature ventricular complexes.","volume":"108","author":"Higuchi","year":"2022","journal-title":"Heart"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.amjcard.2011.08.009","article-title":"Relation of ventricular premature complexes to heart failure (from the Atherosclerosis Risk In Communities [ARIC] Study).","volume":"109","author":"Agarwal","year":"2012","journal-title":"Am J Cardiol"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1097\/CRD.0000000000000262","article-title":"Premature ventricular contractions and cardiomyopathy.","volume":"27","author":"You","year":"2019","journal-title":"Cardiol Rev"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1161\/CIRCEP.114.001530","article-title":"Complications of catheter ablation of ventricular tachycardia: a single-center experience.","volume":"7","author":"Peichl","year":"2014","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1186\/s12872-018-0913-2","article-title":"The safety of catheter ablation for premature ventricular contractions in patients without structural heart disease.","volume":"18","author":"Wang","year":"2018","journal-title":"BMC Cardiovasc Disord"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s10840-019-00655-3","article-title":"Premature ventricular complexes: diagnostic and therapeutic considerations in clinical practice: a state-of-the-art review by the American College of Cardiology Electrophysiology Council.","volume":"57","author":"Gorenek","year":"2020","journal-title":"J Interv Card Electrophysiol"},{"key":"R9-20250504","first-page":"36","article-title":"Efficacy analysis of Yiqi Yangyin Zhenji Decoction in the treatment of coronary heart disease ventricular premature contractions with Qi and Yin deficiency and blood stasis syndrome.","author":"Guo","year":"2020","journal-title":"J Cardiovasc Dis Prev Rehabil"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1016\/j.amjcard.2006.06.061","article-title":"Usefulness of ventricular premature complexes to predict coronary heart disease events and mortality (from the Atherosclerosis Risk In Communities cohort).","volume":"98","author":"Massing","year":"2006","journal-title":"Am J Cardiol"},{"key":"R11-20250504","first-page":"1626","article-title":"Progress in Chinese and Western medicine treatment of ventricular premature contractions.","volume":"10","author":"Zhang","year":"2015","journal-title":"Int J Ttadit Chin Med"},{"key":"R12-20250504","first-page":"1","article-title":"Based on CYP3A4 enzyme to explore the pharmacokinetic effect and mechanism of Xinmai\u2019an tablet on sildenafil.","volume":"38","author":"Sun","year":"2021","journal-title":"J Stud Trace Elem Health"},{"key":"R13-20250504","first-page":"183","article-title":"Clinical observation of Xinmai\u2019an tablet in treating coronary heart disease with ventricular premature beat.","volume":"15","author":"Shao","year":"2013","journal-title":"J Liaoning Univ Tradit Chin Med"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"e183","DOI":"10.1111\/j.1755-5922.2011.00271.x","article-title":"Ginsenoside Re: pharmacological effects on cardiovascular system.","volume":"30","author":"Peng","year":"2012","journal-title":"Cardiovasc Ther"},{"key":"R15-20250504","first-page":"23","article-title":"Xinmai\u2019an tablet in the treatment ofin treatment of premature ventricular contractions due to coronary heart disease 40 cases of curative effect observation.","author":"Qiu","year":"2003","journal-title":"J Chengdu Univ Tradit Chin Med"},{"key":"R16-20250504","first-page":"863","article-title":"Clinical observation on 136 cases of angina pectoris coronary heart disease treated with Xinmai\u2019an tablet.","volume":"25","author":"Sun","year":"2009","journal-title":"J Changchun Univ Tradit Chin Med"},{"key":"R17-20250504","first-page":"1","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation.","author":"Shamseer","year":"2015","journal-title":"BMJ"},{"key":"R18-20250504","doi-asserted-by":"crossref","first-page":"e166","DOI":"10.1016\/j.hrthm.2014.07.024","article-title":"EHRA\/HRS\/APHRS expert consensus on ventricular arrhythmias.","volume":"11","author":"Pedersen","year":"2014","journal-title":"Heart Rhythm"},{"key":"R19-20250504","first-page":"68","article-title":"Guiding principles for clinical research on new drugs of traditional Chinese medicine.","author":"Zheng","year":"2002","journal-title":"Chin J Tradit Med Sci Technol"},{"key":"R20-20250504","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomized trials.","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"R21-20250504","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations.","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"R22-20250504","first-page":"192","article-title":"Analysis of drug therapy for coronary heart disease complicated with arrhythmia.","author":"Xu","year":"2020","journal-title":"J China Med"},{"key":"R23-20250504","article-title":"Evidence-based multi-center randomized controlled clinical trial of integrated traditional Chinese and western medicine in the treatment of ventricular premature beats in coronary heart disease.","author":"Zhou","year":"2013","journal-title":"J South Med Univ"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000032253","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T04:47:32Z","timestamp":1746334052000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000032253"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,9]]},"references-count":23,"journal-issue":{"issue":"49","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000032253","relation":{},"ISSN":["1536-5964"],"issn-type":[{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,9]]}}}